SecBot SecBot
SECBOTREPLAY Home › Report › TEM

TEM · Tempus AI (TEM) filed a 425 investor call transcript reinforcing its…

Tempus AI, Inc. · 425 filed Jul 20, 2026 at 17:23 ET

At the news

BULLISHIMPACT 6/10

425 filed Jul 20, 2026 at 17:23 ET

Tempus AI (TEM) filed a 425 investor call transcript reinforcing its July 20, 2026 definitive agreement to acquire Personalis (PSNL). The call highlighted NeXT Personal MRD test volumes growing 38% QoQ to ~9,000 tests in Q2, with only 10% of Tempus's sales force currently selling the assay, suggesting significant runway for expansion. The $1.5B net stock-for-stock deal is expected to close late 2026 or early 2027, with Tempus reiterating its 2027 EBITDA and FCF positivity target.

  • Tempus acquiring Personalis at $16.25/share, representing a 6% premium to Friday's close and 28% premium to the 30-day VWAP; total consideration $1.5B net of existing stake
  • NeXT Personal MRD test volumes grew 38% QoQ to ~9,000 tests in Q2 2026 (from ~6,500 in Q1)
  • Only 10% of Tempus's sales force currently sells MRD solutions, indicating future volume growth potential as more reps are equipped
  • Consideration structured as 100% stock with Tempus option to pay up to 50% in cash; floating exchange ratio capped at 0.3356

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access